<DOC>
	<DOCNO>NCT01059617</DOCNO>
	<brief_summary>This study design characterize safety immunogenicity ' pandemic influenza ( H1N1 ) candidate vaccine GSK2340274A adult 19 40 year never receive influenza vaccination .</brief_summary>
	<brief_title>Safety Immune Response Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol ( e.g. , completion diary card , return followup visit ) . Written inform consent obtain subject . Male female adult , 1940 year age time first vaccination . Body weight least 110 pound ( 49.9 kg ) . Safety laboratory test result within parameter specify protocol . Satisfactory baseline medical assessment physical examination ( stable health status exclusionary condition ) . Stable health status define absence health event satisfy definition serious adverse event , change ongoing drug therapy due therapeutic failure symptom drug toxicity , within one month prior enrollment . Comprehension study requirement , ability comprehend comply procedure collection safety data , express availability require study period , ability willingness attend schedule visit document signature inform consent document . Access consistent mean telephone contact , may either home workplace , land line , mobile , NOT pay phone multipleuser device ( i.e. , commonuse phone serve multiple room apartment ) . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy , postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series Previous vaccination A/California/7/2009 ( H1N1 ) vlike virus vaccine A medical history physicianconfirmed infection A/California/7/2009 ( H1N1 ) vlike virus . Prior receipt time seasonal influenza vaccine . Planned administration vaccine foreseen study protocol ( include influenza vaccine study vaccine ) Days 0 Day 164 phlebotomy . Administration license vaccine within 30 day first study vaccine dose . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Receipt systemic glucocorticoid ( e.g. , prednisone ≥ 0.5 mg/kg/day , ≥ 10 mg/day [ whichever less ] 14 consecutive day ) within one month prior study enrolment , cytotoxic immunosuppressive drug within six month study enrolment . Topical , intraarticularly inject , inhaled glucocorticoid , topical calcineurin inhibitor imiquimod allow . Receipt immunoglobulins and/or blood product within 9 month study enrolment plan administration product study period . Presence evidence substance abuse neurological psychiatric diagnosis , even stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . History anemia . Presence temperature ≥ 38.0ºC ( ≥100.4ºF ) , ( oral temperature assessment prefer ) , acute symptom great `` mild '' severity schedule date first vaccination Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . ( No laboratory test require . ) Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose acetylsalicylic acid , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome within six week receipt vaccine . Any known suspected allergy constituent influenza vaccine ( include egg proteins mercurial preservative ) ; history anaphylactictype reaction consumption egg ; history severe adverse reaction vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin ( βHCG ) test result prior first vaccination . Lactating nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Pandemic</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK2340274A</keyword>
	<keyword>H1N1</keyword>
	<keyword>Influenza</keyword>
</DOC>